STAT6 degradation is expected to provide a clinical benefit for patients with Type 2 inflammatory diseases, including asthma.
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track ...
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...
The Kentucky Department of Fish and Wildlife Resources says a wildlife management area along the Kentucky River has expanded ...
Korea’s leading telecom operators are pulling back from stand-alone streaming services, as rising costs and fierce ...
POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA ...
Later, in a Fox News interview, Trump threatened to impose a 50 per cent tariff on Chinese imports if Beijing tries to help ...
Once they have brought Washington and Tehran to the negotiating table on Saturday, the Pakistani officials will try to steer ...
The Chosun Ilbo on MSN
Sports leaders under fire for reckless conduct
The reckless conduct of leaders from the professional baseball league and national football team, both deeply loved by ...
Khaleej Times on MSN
Artemis II crew hours away from high-stakes re-entry after historic moon journey
Artemis astronauts gird for re-entry and splashdown ...
Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...
A new study found that KT tape may not be effective for long-term pain relief or injury recovery. Experts weigh in on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results